Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer

Cancer Research

Volumn 74, Issue 12, 2014, Pages 3259-3270

  Mathé, Ewy A ^a,b   Patterson, Andrew D ^c   Haznadar, Majda ^b   Manna, Soumen K ^b   Krausz, Kristopher W ^b   Bowman, Elise D ^b   Shields, Peter G ^f   Idle, Jeffrey R ^g   Smith, Philip B ^d   Anami, Katsuhiro ^b   Kazandjian, Dickran G ^b   Hatzakis, Emmanuel ^e   Gonzalez, Frank J ^b   Harris, Curtis C ^b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Department of Veterinary and Biomedical Sciences   (United States)

^d Metabolomics Core Facility   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CREATININE RIBOSIDE; N ACETYLNEURAMINIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE URINE LEVEL; EARLY DIAGNOSIS; FEMALE; HEALTH STATUS; HUMAN; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOME; METABOLOMICS; NON INVASIVE PROCEDURE; PASSIVE SMOKING; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; QUANTITATIVE ANALYSIS; SMOKING HABIT; URINALYSIS; VALIDATION PROCESS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CREATINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; METABOLOME; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RIBONUCLEOSIDES; ROC CURVE; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84903466700     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0109     Document Type: Article

References (56)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:749-50.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Boyle P LB, editor. The World Cancer Report 2008. Lyon, France: IARC; 2008.
4. Horner M, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
5. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144:33-8.
6. Kang JX. Identification of metabolic biomarkers for personalized nutrition. J Nutrigenet Nutrigenomics 2012;5:I-II.
7. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
8. Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 2004;231:440-5. (Pubitemid 38552902)
9. Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K. Screening and early detection of lung cancer. Ann Oncol 2012;23 Suppl 10:x320-7.
10. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res 2012;5:992-1006.
11. Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013;119:356-62.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
13. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
15. Antoniu SA. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703. Expert Opin Ther Targets 2011;15:351-3.
16. Schmidt C. Urine biomarkers may someday detect even distant tumors. J Natl Cancer Inst 2009;101:8-10.
17. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95. (Pubitemid 43794421)
18. Henneges C, Bullinger D, Fux R, Friese N, Seeger H, Neubauer H, et al. Prediction of breast cancer by profi ling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer 2009;9:104.
19. Hsu WY, Chen WT, Lin WD, Tsai FJ, Tsai Y, Lin CT, et al. Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clin Chim Acta 2009;402:31-7.
20. Jeng LB, Lo WY, Hsu WY, Lin WD, Lin CT, Lai CC, et al. Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis. Rapid Commun Mass Spectrom 2009;23:1543-9.
21. Xu G, Schmid HR, Lu X, Liebich HM, Lu P. Excretion pattern investigation of urinary normal and modi fi ed nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed Chromatogr 2000;14:459-63.
22. Borek E, Baliga BS, Gehrke CW, Kuo CW, Belman S, Troll W, et al. High turnover rate of transfer RNA in tumor tissue. Cancer Res 1977;37:3362-6. (Pubitemid 8169926)
23. Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol 2008;4:93-102. (Pubitemid 351372610)
24. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem 2007;363:185-95. (Pubitemid 46428214)
25. Matsumura K, Opiekun M, Oka H, Vachani A, Albelda SM, Yamazaki K, et al. Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer. PLoS ONE 2010;5:e8819.
26. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
27. Yang Q, Shi X, Wang Y, Wang W, He H, Lu X, et al. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J Sep Sci 2010;33:1495-503.
28. Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011;71:6749-57.
29. Fan TW, Lane AN, Higashi RM. The promise of metabolomics in cancer molecular therapeutics. Curr Opin Mol Ther 2004;6:584-92. (Pubitemid 40074978)
30. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006;66:10795-804. (Pubitemid 44876975)
31. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009;18:260-6.
32. Hecht SS, Murphy SE, Stepanov I, Nelson HH, Yuan JM. Tobacco smoke biomarkers and cancer risk among male smokers in the Shanghai Cohort Study. Cancer Lett 2012 Jul 20. [Epub ahead of print].
33. Hsu PC, Zhou B, Zhao Y, Ressom HW, Cheema AK, Pickworth W, et al. Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. J Proteome Res 2012;2:679-91.
34. Strathmann FG, Hoofnagle AN. Current and future applications of mass spectrometry to the clinical laboratory. Am J Clin Pathol 2011;136:609-16.
35. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th ed: New York: Springer-Verlag; 2010.
36. Breiman L. Random Forests. Mach Learn 2001;45:5-32. (Pubitemid 32933532)
37. Ho TK. Random Decision Forest. In: Proceedings of the 3rd International Conference on Document Analysis and Recognition, Montreal, QC, 14-16 August 1995. pp. 278-82.
38. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (Methodological) 1995;57:11.
39. Breslow NE. Analysis of survival data under the proportional hazards model. Int Stat Rev/Rev Int de Stat 1978;43:45-57.
40. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
41. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. (Pubitemid 41007845)
42. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-18. (Pubitemid 350232227)
43. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
44. Neri B, Bartalucci S, Gemelli MT, Tommasi M, Bacalli S. Creatine kinase isoenzyme BB: a lung cancer associated marker. Int J Biol Markers 1988;3:19-22.
45. Gazdar AF, Zweig MH, Carney DN, Van Steirteghen AC, Baylin SB, Minna JD. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res 1981;41:2773-7. (Pubitemid 11071811)
46. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
47. Iwaoka WT, Krone CA, Sullivan JJ, Johnson CA. Effect of pH and ammonium ions on mutagenic activity in cooked beef. Cancer Lett 1981;12:335-41. (Pubitemid 11116339)
48. Schauer R. Sialic acids: fascinating sugars in higher animals and man. Zoology 2004;107:49-64. (Pubitemid 40427891)
49. Krolikowski FJ, Reuter K, Waalkes TP, Sieber SM, Adamson RH. Serum sialic acid levels in lung cancer patients. Pharmacology 1976;14:47-51.
50. Ghosh PC, Lockwood E, Pennington GW. Abnormal excretion of corticosteroid sulphates in patients with breast cancer. Br Med J 1973;1:328-30.
51. Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013;368:1477-88.
52. Bornstein SR, Chrousos GP. Clinical review 104: Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999;84:1729-36. (Pubitemid 30644284)
53. Bornstein SR, Engeland WC, Ehrhart-Bornstein M, Herman JP. Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab 2008;19:175-80. (Pubitemid 351847836)
54. Heavner DL, Richardson JD, Morgan WT, Ogden MW. Validation and application of a method for the determination of nicotine and five major metabolites in smokers' urine by solid-phase extraction and liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2005;19:312-28. (Pubitemid 40872658)
55. Mellert W, Kapp M, Strauss V, Wiemer J, Kamp H, Walk T, et al. Nutritional impact on the plasma metabolome of rats. Toxicol Lett 2011;207:173-81.
56. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome. Annual review of pharmacology and toxicology 2012;52:37-56.